Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Latest Loncar positions and weighs:
http://www.loncarindex.com/cancer-immunotherapy-index-weights
CNCR
Got lucky. Have been eyeing it more closely daily looking for a bottom before a run-up to data which came unfortunately prematurely. Also was watching NLNK. Brad Loncar (who I follow daily on Twitter) has both in his portfolio.
https://investorshub.advfn.com/Loncar-Cancer-Immunotherapy-ETF-(NASDAQ-CNCR)-CNCR-30772/
INCY
Sold @ $8.50 my pre-set target for today. Look to re-enter on any pullback -- bid order in. Still a lot of room up and great chart.
ADT
Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel
GlobeNewswire•April 5, 2018
PETALUMA, Calif., April 05, 2018 (GLOBE NEWSWIRE) --
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for management of dermatological conditions and advanced tissue care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy as well for use following superficial chemical peels. It may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.
Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center, and Tennessee Clinical Research Center, all located in Nashville, Tennessee, commented, “This antimicrobial post-treatment gel is a promising new tool for all dermatologists and aesthetic clinicians who are looking to better manage medical procedures, post-procedure itch and pain associated with procedures including laser skin resurfacing, while promoting enhanced healing and protection against secondary infections. In our clinical testing to date, we have seen dramatically improved outcomes with quicker healing times and less patient discomfort when this advanced technology is added to our procedure management protocol.”
"This approval is one in a series that further fortifies Sonoma’s portfolio of innovative antimicrobial dermatology products,” said Jim Schutz, Sonoma Pharmaceutical's CEO. “With our continuing efforts working with the FDA to provide best-in-class products as alternatives to topical steroids and topical antibiotics, dermatologists should have increased confidence in our growing product portfolio without concern for the troubling side effects found in dated treatments.”
For more information, visit IntraDerm Pharmaceuticals at www.intraderm.com or phone 1-855-317-1107.
About Laser Skin Resurfacing
According to the Clinical, Cosmetic and Investigational Dermatology Journal, medical and aesthetic skin procedures have seen a steady surge within the last decade, and a higher demand for skin rejuvenation practices. In 2013 in the United States, dermatologic surgeons performed over 9.5 million treatments, an almost 22% increase from the previous year, with a rising number of treatments involving skin resurfacing in the areas of laser/light/energy-based procedures (2.25 million), chemical peels (1.1 million), and microdermabrasion (974,000).
Laser skin resurfacing, also known as a laser peel, laser vaporization and lasabrasion, can reduce facial wrinkles, scars and blemishes. Newer laser technologies provide surgeons with a new level of control in laser surfacing, permitting extreme precision, especially in delicate areas. The laser beam used in laser resurfacing will remove outer layer of skin, called the epidermis. It simultaneously heats the underlying skin, called the dermis. This action works to stimulate growth of new collagen fibers. As the treated area heals, the new skin that forms is smoother and firmer. Common side effects include redness of the skin, swelling of the treated area, itch, pain and moderate irritation similar to the feeling produced by a mild sunburn.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for management of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
__________________________________________
https://finance.yahoo.com/news/sonoma-pharmaceuticals-announces-fda-approval-110500211.html
(In for a small position; been bid sitting and getting partial fills)
FWIW, in the last 5 minutes went from $24.20 to $24.08.
This from BarChart. They were exactly on spot:
High 24.23 High
24.18 38.2% Retracement From 52 Week Low
Pivot Point 2nd Level Resistance 24.08
Last 24.08 Last
https://www.barchart.com/stocks/quotes/KR/cheat-sheet
KR
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclob...
Date : 04/03/2018 @ 7:00AM
Source : GlobeNewswire Inc.
Phase 3 HONOR Study Enrollment Continues and Interim Results of the First 50 Percent of Participants Expected in Third Quarter 2018
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced that 50 percent of the planned total number of participants have been randomized in the Phase 3 HONOR study evaluating Tonmya®*, or TNX-102 SL 5.6 mg, for the bedtime treatment of military-related posttraumatic stress disorder (PTSD). Tonmya for the treatment of PTSD has been designated a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). Clinical evidence from the Phase 2 study of Tonmya showed a potential improvement over existing therapies used to treat military-related PTSD. The FDA is committed to expediting the development and review of Tonmya for PTSD.
An interim analysis of the first 50 percent of randomized participants will be conducted shortly after the 12-week treatment period has been completed by these participants. Topline efficacy results from the interim analysis are expected in the third quarter of this year.
"Reaching randomization of 50 percent for the HONOR study is an important milestone for Tonix,” said Seth Lederman, M.D., President and Chief Executive Officer. “Based on the current enrollment rate, topline data from the full study is expected in the fourth quarter of 2018, if 550 participants are needed to complete the study.”
The interim analysis will be reviewed by an Independent Data Monitoring Committee, or IDMC, which will review unblinded data from this first 50 percent of participants and make one of three recommendations: (1) stop the trial for success; (2) continue to enroll the full study as planned; or (3) continue to enroll with a specified increase in the total number of participants in the full study.
At the Cross-disciplinary Breakthrough Therapy meeting, the FDA indicated that a single-study New Drug Application (NDA) approval is possible, based on the interim or end-of-study analysis of the HONOR study, if the results are statistically persuasive. The company is ready to file an NDA for Tonmya for the treatment of PTSD in 2019 in the event of a persuasive outcome of the HONOR study.
*Tonmya has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for PTSD. TNX-102 SL is an investigational new drug and has not been approved for any indication.
About Tonmya and the Phase 3 HONOR Study
Tonmya is a sublingual transmucosal tablet formulation of cyclobenzaprine that is in Phase 3 development. PTSD is a serious condition characterized by chronic disability, inadequate treatment options, especially for military-related PTSD, and an overall high utilization of healthcare services that contributes to significant economic burdens. In a Phase 2 study, Tonmya 5.6 mg (2 x 2.8 mg tablets) was found to be effective in treating military-related PTSD, which formed the basis of the Breakthrough Therapy designation granted by the FDA. Tonix is currently conducting a Phase 3 trial of Tonmya in military-related PTSD in the U.S., the HONOR study, which is a 12-week randomized, double-blind, placebo-controlled trial evaluating the efficacy of Tonmya 5.6 mg in participants with military-related PTSD. This two-arm, adaptive-design trial is targeting enrollment of up to approximately 550 participants in approximately 40 U.S. sites. An unblinded interim analysis will be conducted now that the study has accumulated efficacy results from approximately 275 randomized participants. In a Cross-Disciplinary Breakthrough Therapy meeting, the FDA confirmed that (i) a single-study NDA approval could be possible if the topline data from the HONOR study are statistically very persuasive, and (ii) an additional abuse assessment study is not required for the NDA filing. Additional details of the HONOR study are available at www.thehonorstudy.com or https://clinicaltrials.gov/ct2/show/NCT03062540.
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead product candidate, Tonmya, or TNX-102 SL, is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer’s disease. A Phase 2 IND (Investigational New Drug) application was submitted in March 2018 after completion of a successful pre-IND meeting with the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but designed for daytime dosing. Tonix’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission (the “SEC”) on March 9, 2018, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Contacts
Jessica Morris (investors)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(212) 980-9159
Rich Allan (media)
Russo Partners
rich.allan@russopartnersllc.com
(646) 942-5588
____________________________________________________
TNXP
Assessing Invitae's Flub This Week
Apr. 1, 2018 10:22 AM ET|9 comments |About: Invitae (NVTA)
Never apologize, mister, it’s a sign of weakness.” ? John Wayne
The market has been volatile since early February, especially in the high beta parts of the market like biotech and small caps in general. For those needing to add 'balance' to their portfolio, I do recommend Tim Plaehn; a friend & colleague of mine at Investors Alley as well as a contributor here on SeekingAlpha. Tim runs the Dividend Hunter newsletter which offers a solid & diverse selection of attractive high yield plays. The service is now over 6,500 active subscribers and can be had HERE for the rock bottom price of $49 (It usually is $99) for the first year. There are few better bargains around. He also has a free report on five dividend stocks he likes in 2018, which can be downloaded gratis HERE.
Click link for chart/table
Because no retreat from the world can mask what is in your face.” ? Gregory Maguire,
I have started to believe in recent years that the most important executive at most small Tier 3 and Tier 4 biotech/biopharma concerns is not the CEO. It is also not the Chief Medical Officer or the head of Marketing. It is the CFO.
Planning for and funding operational needs while clearly communicating and keeping to plans with shareholders are paramount to credibility (and one’s stock price). Doing this while ensuring not placing the company in a position that puts it behind the ‘eight ball’ in capital raise negotiations can be a tricky balancing act. Those that do it well can enhance the valuation on their stock. Doing it incompetently, can erode stock value.
We saw that again this week as the stocks of Sorrento Therapeutics (SRNE) and genetic testing concern Invitae (NVTA) because of poorly received capital raises. Meanwhile, investors barely batted an eye on similar raises that were well received with Xencor (XNCR) and Heron Therapeutics (HRTX). We will be doing an exclusive 'deep dive' around Sorrento later this week for members of The Biotech Forum. In today's instablog post, we will take a look at Invitae's flub.
The company decided to raise some $55 million this week via a secondary offering. It was not the amount of the raise that set investors, it was the price ($4.50 a share) of the offering. Given where the stock ($7.02 a share) started the week, it seemed more of a 'fire sale' than a capital raise.
Click link for chart/table
Invitae was somewhat under the gun as it has just over $75 million in cash and marketable securities on the balance sheet at the end of 2017. Cash used in operating activities in 2017 amounted to $97.7 million which gave it at least three quarters of 'cash burn' left. Quarterly cash burn should start to come down markedly as samples/sales ramp up significantly in the year ahead. My opinion is that the company did a very poor job in negotiating the terms of this deal.
Click link for chart/table
Source: Company Presentation
As can been seen in the chart above, the company is in the midst of a major period of growth. Management has guided they expect at least $120 million in revenue in FY2018 after just less than $70 million in FY2017. They also expect to test at least 250,000 samples and continue to bring the cost per test down.
Click link for chart/table
Source: Company Presentation
Invitae has a huge secular tailwind behind it as the genetic testing market is expected to roughly triple to a ~$10 billion annual pace over the next five to six years. I also think eventually all the testing data the company is warehousing will turn into a valuable data analytics asset as well.
Image result for buy-write strategy I decided to 'hold my nose' and double down on Invitae using Buy-Write orders to help mitigate some risk late this week. I also find it somewhat comforting that Julian Baker of the Baker Bros. bought just over $5 million of the secondary offering. If one of the best investors in the healthcare space can get over his disappointment on how this capital raise was conducted, I guess I can as well.
It is the bungled crime that brings remorse.” ? P.G. Wodehouse, Love Among the Chickens
Image result for investor toolboxFor those that want to learn about more advanced option strategies to put in their investor 'toolbox', I highly recommend the free 30 minute report and 7 minute video my Investors Alley's colleague Jay Soloff has put together. Jay has been teaching about and using option strategies successfully for two decades. The free video and report can be downloaded HERE
__________________________________________
https://seekingalpha.com/instablog/498952-bret-jensen/5138357-assessing-invitaes-flub-week
NVTA
Out @ $6.97. Look to get back in. Long weekend which could be good or bad. Want to see the effects of Trump's statement today that infrastructure may be delayed until after the Nov election.
CLF
Got lucky on that. Price action didn't feel right. Also as I had been posting for days NDAQ and EDGX were really taking advantage of the wide spread and somewhat low volume -- they made a lot from this stock.
I believe in the company and will be back.
ALT
Joined you today @ $2.97. Like at this level:
Book/sh 3.16 P/B 0.94 EPS next Y 23.20% ROA -72.30% Target Price 9.67 Perf Year -27.21% Cash/sh 3.03 Quick Ratio 12.40 Current Ratio 12.40
https://finviz.com/quote.ashx?t=tnxp&ty=c&ta=1&p=d
TNXP
The big loser is top holder because all shares would be bought substantially above $4.50. A quick calculation would be they paid ~$9.52 so they lost about $35M. Would assume they are buying them up today unless they had already unloaded and that was the reason for the offering.
"Brothers Advisors, LLC 7,288,300 Dec 30, 2017 13.57% $69,530,381"
NVTA
This Explains Why Invitae Is Sinking Today
Brian Feroldi, The Motley Fool
Motley FoolMarch 27, 2018
What happened
In response to the high-growth genetic testing company announcing plans for a secondary common stock offering, shares of Invitae (NYSE: NVTA) fell 17% as of 10:40 a.m. EDT on Tuesday.
So what
Invitae plans to raise $50 million through a secondary common stock. As usual, the underwriters of the deal are also being granted an option to purchase up to an additional $7.5 million worth of stock at the offering price. When combined, this transaction could raise up to $57.5 million before subtracting fees.
For perspective, Invitae's market cap right now is about $320 million, so this deal could dilute current shareholders by up to 18%.
The timing of this capital raise is a bit of a head-scratcher because Invitae's stock has now fallen by about 34% since the start of 2018. What's more, the company just increased its credit facility by $20 million in February, so you wouldn't think that a common stock offering would be necessary so soon.
Given the potential dilution, it isn't hard to figure out why Wall Street isn't happy about today's update.
Businessman with coins falling through his hands
More
Image source: Getty Images.
Now what
Invitae burned through $98 million in 2017 and ended the year with about $76 million in cash. When adding in the recent credit facility expansion and today's common stock offering, the company should now have access to enough capital to keep it in hypergrowth mode for at least another year.
On the flip side, it still has a long way to go before it starts to reach profitability, so today's capital raise isn't likely to be its last. For that reason, my plan is to keep this intriguing company as a watchlist idea for the foreseeable future.
_________________________________________________
https://finance.yahoo.com/news/explains-why-invitae-sinking-today-155600515.html?_fsig=l4uoFgAeA5AgCaxyZB14yg--
NVTA
Thanks for the advice. Generally don't stay here long unless something out of the ordinary happens and generally use charts for technicals. Also check X and AKS before trading for comparison. Haven't ever checked iron ore daily other than from Tweets. Looks to me as if this is a good resource:
http://markets.businessinsider.com/commodities/iron-ore-price
Also see Twitter account:
https://twitter.com/metalbulletin
What do you use for checking?
CLF
Back in NVTA @ $6.20. Seem to recall that after the last offering didn't stay down very long (Baker Bro is huge holder).
NVTA
See this Tweet: "$CLF average P/E ratio for steel sector is 15. Fortune 500 is 24."
Are those figures about right? Thanks.
CLF
Keeping the merger talk alive:
__________________________________________________
What a Target-Kroger Merger Mean for Rivals By Shoshanna Delventhal | March 26, 2018 — 12:42 PM EDT
On Friday, news broke that retail chain Target Corp. (TGT) and grocery giant Kroger Co. (KR) were discussing a possible merger, as first reported by Fast Company, citing several people with knowledge of the matter. While sources later told CNBC that the information was false and the talks were instead about a Shipt partnership, a tie up could make sense for the two traditional brick-and-mortar retailers as they scramble to compete against e-commerce and cloud computing giant Amazon.com Inc. (AMZN)
As Seattle-based retail behemoth Amazon demonstrates that no industry is safe from its disruption, including grocery, apparel, health care and entertainment, its new rivals are being pressured to scale up and drive down prices. Amazon, with its deep pocks, massive scale and global customer reach, deals with investors that are less critical of short-term numbers, allowing the company to incur an initial loss if it means an opportunity for a long-term leadership position in a new market. In June, the company's $13.7 billion Whole Foods acquisition sent grocery stocks plummeting as it offered Amazon its first physical retail stores.
"From a high level, both Kroger and Target have deficiencies that make competing in this new world harder," said Wolfe Research analyst Scott Mushkin, as quoted in a story published Monday by The Street. In the "new world" of retail, big box retailers such as Target and Walmart Inc are doubling down on their omnichannel strategies, beefing up online businesses, improving the in-store experience and launching new lines of branded products across segments such as home goods and apparel.
Deal Would Boost Target's Grocery Business
The conversations between the two companies, which reportedly started last summer and have continued into this year, would work to bolster Target's grocery business, while offering Kroger customers more access to merchandise and online retail. In 2017, their combined annual revenue amounted to $195 billion, versus Walmart's $485.9 billion and Amazon's $177.9 billion.
Investors have sold-off Kroger's stock in the recent months, worried about its underinvestment in its online strategy. The grocery chain reportedly attempted to buy wholesale e-commerce brand Boxed, but the deal dissolved after Kroger offered less than its $470 valuation. A tie up with Target would integrate Kroger with on-demand grocery delivery service Shipt, which it also failed to solidify a deal with and was instead purchased by Target for $550 million.
The partnership would give the firms a greater hedge against Walmart, the world's largest retailer, with the largest share of the $800 billion U.S. grocery market. The Bentonville, Arkansas-based company has teamed up with Alphabet Inc.'s (GOOG) Google Home for voice-activated home shopping, competing against Amazon's Alexa, while it doubles down on its delivery services and plans to launch a Millennial-focused grocery brand on its online platform Jet.com.
Overall, a merger between Target and Kroger would expand the market opportunity for both companies, offering Kroger the infrastructure it needs for a new digital grocery landscape, while enhancing Target's grocery business with greater quality and scale. (See also: Amazon Tops Alphabet, Is Now No. 2 in Market Cap.)
Read more: What a Target-Kroger Merger Mean for Rivals | Investopedia https://www.investopedia.com/news/what-target-kroger-merger-would-mean-amazon-walmart/#ixzz5AtBbZ72F
Follow us: Investopedia on Facebook
_____________________________________________
KR
Out @ $3.95. Will try to re-enter but playing the wide spread and could not resist the profit.
SNOA
Out @ $1.51 for essentially even trade (but costly in mental frustration). May regret it but see the MMs do the same each day and down today whereas the sector is up big. Would expect more positive sentiment just days prior to a catalyst.
ALT
Cleveland-Cliffs Inc. to Announce First-Quarter 2018 Results on April 20
7:00 AM ET 3/26/18 | BusinessWire
CLEVELAND--(BUSINESS WIRE)--March 26, 2018--
Cleveland-Cliffs Inc. (NYSE:CLF) today said it will be announcing first-quarter 2018 financial results before the U.S.-market open on Friday, April 20, 2018.
The Company invites interested parties to listen to a live broadcast of a conference call with securities analysts and institutional investors to discuss the results.
When: Friday, April 20, 2018, at 10 a.m. ET
Hosts: Lourenco Goncalves, Chairman, President and Chief Executive
Officer
Tim Flanagan, Executive Vice President and Chief Financial
Officer
Web Address: http://www.clevelandcliffs.com
If you are unable to participate during the live webcast, the call will also be archived at the web address listed above.
About Cleveland-Cliffs Inc.
Founded in 1847, Cleveland-Cliffs Inc. is the largest and oldest independent iron ore mining company in the United States. We are a major supplier of iron ore pellets to the North American steel industry from our mines and pellet plants located in Michigan and Minnesota. Additionally, we operate an iron ore mining complex in Western Australia. By 2020, Cliffs expects to be the sole producer of hot briquetted iron (HBI) in the Great Lakes region with the development of its first production plant in Toledo, Ohio. Driven by the core values of safety, social, environmental and capital stewardship, our employees endeavor to provide all stakeholders with operating and financial transparency. For more information, visit http://www.clevelandcliffs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180326005297/en/
CONTACT: Cleveland-Cliffs Inc.
MEDIA:
Patricia Persico, 216-694-5316
Director, Corporate Communications
or
INVESTORS:
Paul Finan, 216-694-6544
Director, Investor Relations
SOURCE: Cleveland-Cliffs Inc.
Copyright Business Wire 2018
> Dow Jones Newswires
March 26, 2018 07:00 ET (11:00 GMT)
_______________________________________________
CLF
Ditto from yesterday, same MMs. Just saw ~11,000 shares bought at $1.53 and then take down with a 100 share sale $1.48.
Big volume today.
ALT
Cold water thrown on Kroger-Target merger talk
Mar. 23, 2018 8:48 AM ET|About: Kroger Co. (KR)|By: Clark Schultz, SA News Editor
Excitement over a potential merger between Kroger (NYSE:KR) and Target (NYSE:TGT) is already receding after CNBC reports that the two companies are only talking about a Shipt partnership. Target acquired online grocery player Shipt in December for $550M.
Kroger is now only up 2.61% in premarket action after soaring over 12% earlier. Target is still up about 2%.
______________________________________________________
KR
Back in @ $3.65. Very low volume day. Ask set, hope for a 1-2 day trade.
SNOA
Target and Kroger in merger talks: report
Published: Mar 23, 2018 8:31 a.m. ET
By TONYA GARCIA
REPORTER
Shares of Target Corp. TGT, +1.77% and Kroger Co. KR, +3.46% jumped 2.7% and 6.9% respectively on a report from Fast Company that the two companies are in merger talks. The retailers began discussions last summer about a partnership, and talked again in the fall. Neither company commented for the story. Target has searched for ways to improve its grocery business. And both companies, along with the rest of the retail sector, are grappling with Amazon.com Inc. AMZN, -0.21% and its acquisition of Whole Foods Market. Fast Company points out that a number of grocers, including Kroger and Albertson's, have struck deals with third-parties like Instacart to beef up digital grocery and delivery services. And Walmart Inc. has either tested or enacted various initiatives, like curbside pick-up and in-home delivery, to remain competitive. Target announced that it was acquiring Shipt, an online same-day grocery delivery service, in December. Target shares are up 29.6% for the past year, Kroger shares are down 20.1% for the period, and the S&P 500 index SPX, -2.52% is up 12.7% for the last 12 months.
___________________________________________
KR
Kroger and Target said to be in merger talks
Mar. 23, 2018 8:19 AM ET|About: Kroger Co. (KR)|By: Clark Schultz, SA News Editor
Shares of Kroger (NYSE:KR) race higher in premarket trading after Fast Company reports that the company is talking to Target (NYSE:TGT) about a potential merger.
Sources indicate that discussions between the two retail majors started up last summer and are still ongoing.
Kroger is up 6.93% premarket to $25.01. Target is down 0.29% to $68.69.
_________________________________________________
KR
Seeing the same each day -- after the opening and the first few hours EDGX and NSDQ become the only MMs on high bid and low ask. For 2-3 hours they merely trade shares back and forth within a small range for close to 100K of shares. The pps doesn't move and the MMs make their percentage cut from every trade. They are the only winners. Suspect NSDQ is the lead MM on this stock. Used to know a website wherein you could see how many shares of a stock are currently owned by every MM, but can't find it now.
I've a real love/hate (frustration) with this stock.
ALT
Altimmune to Announce Year End 2017 Financial Results on March 29
March 20, 2018 16:01 ET | Source: Altimmune, Inc.
GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) --
Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29.
Conference Call Details
Date: Thursday, March 29
Time: 8:30am Eastern Time
Domestic: 866-548-4713
International: 323-794-2093
Conference ID: 6280732
Webcast: http://public.viavid.com/index.php?id=128569
Replays, Available through April 12th:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 6280732
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
enright@altimmune.com
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com
_______________________________________
ALT
Back in @ $1.50. Leary due to the unknown of the date for the financials, but good entry price.
ALT
Been watching it from the September lows but always wanting a big dip. Finally got one. You must be doing well if you have been in for a half year or so -- and been getting a small divi along the way.
KR
Kroger's Fred Meyer plans to phase out firearms business
Reuters ReutersMarch 19, 2018
(Reuters) -
Kroger Co's (KR.N) superstore chain Fred Meyer said it would exit its firearms business, two weeks after deciding to stop selling guns and ammunition to those under the age of 21.
Earlier this month, Kroger joined other U.S. retailers such as Walmart Inc (WMT.N) and Dick's Sporting Goods Inc (DKS.N) to bar the sale of firearms to those under 21, following a deadly shooting at a Florida high school.
Fred Meyer said it was working on plans to phase out sales of firearms and ammunition.
"This is a victory for communities and for common sense. And it's a positive step for our pension fund beneficiaries and for public safety," New York City Comptroller Scott Stringer, who oversees the city's public pension funds, said in a statement. Stringer said he had called for Kroger to cease selling firearms last year.
Several large money management firms that own shares in gun makers, including BlackRock Inc (BLK.N), the world's largest asset manager, and State Street Corp (STT.N), have felt the heat following the Florida massacre and have sought answers from gun makers and distributors.
Fred Meyer said the firearm business generated about $7 million annually, while it also highlighted "softening consumer demand."
Fred Meyer operates 133 stores in Alaska, Idaho, Oregon and Washington and sells firearms in 43 of them.
(Reporting by Nivedita Balu in Bengaluru; Editing by Sriraj Kalluvila and Leslie Adler)
____________________________________________
https://finance.yahoo.com/news/krogers-fred-meyer-plans-phase-005807650.html
Should be a positive move given the overall public sentiment.
KR
Just a matter of when to hop. Trying to rebound as of now. Good long term prospect.
ADT